261 related articles for article (PubMed ID: 22858663)
1. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
[TBL] [Abstract][Full Text] [Related]
2. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
Serres F; Pouchelon JL; Poujol L; Lefebvre HP; Trumel C; Daste T; Sampedrano CC; Gouni V; Tissier R; Hawa G; Chetboul V
J Vet Cardiol; 2009 Dec; 11(2):103-21. PubMed ID: 19850546
[TBL] [Abstract][Full Text] [Related]
3. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
[TBL] [Abstract][Full Text] [Related]
5. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
Hezzell MJ; Block CL; Laughlin DS; Oyama MA
J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
[TBL] [Abstract][Full Text] [Related]
6. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
8. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats.
Fox PR; Oyama MA; Reynolds C; Rush JE; DeFrancesco TC; Keene BW; Atkins CE; Macdonald KA; Schober KE; Bonagura JD; Stepien RL; Kellihan HB; Nguyenba TP; Lehmkuhl LB; Lefbom BK; Moise NS; Hogan DF
J Vet Cardiol; 2009 May; 11 Suppl 1():S51-61. PubMed ID: 19394287
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease.
Fine DM; DeClue AE; Reinero CR
J Am Vet Med Assoc; 2008 Jun; 232(11):1674-9. PubMed ID: 18518809
[TBL] [Abstract][Full Text] [Related]
10. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs.
Oyama MA; Rush JE; Rozanski EA; Fox PR; Reynolds CA; Gordon SG; Bulmer BJ; Lefbom BK; Brown BA; Lehmkuhl LB; Prosek R; Lesser MB; Kraus MS; Bossbaly MJ; Rapoport GS; Boileau JS
J Am Vet Med Assoc; 2009 Dec; 235(11):1319-25. PubMed ID: 19951101
[TBL] [Abstract][Full Text] [Related]
11. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
[TBL] [Abstract][Full Text] [Related]
12. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease.
Boswood A; Dukes-McEwan J; Loureiro J; James RA; Martin M; Stafford-Johnson M; Smith P; Little C; Attree S
J Small Anim Pract; 2008 Jan; 49(1):26-32. PubMed ID: 18005104
[TBL] [Abstract][Full Text] [Related]
14. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease.
Moonarmart W; Boswood A; Luis Fuentes V; Brodbelt D; Souttar K; Elliott J
J Small Anim Pract; 2010 Feb; 51(2):84-96. PubMed ID: 20070494
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of natriuretic peptides in dogs with mitral valve disease.
Tarnow I; Olsen LH; Kvart C; Hoglund K; Moesgaard SG; Kamstrup TS; Pedersen HD; Häggström J
Vet J; 2009 May; 180(2):195-201. PubMed ID: 18675567
[TBL] [Abstract][Full Text] [Related]
16. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy.
Schober KE; Hart TM; Stern JA; Li X; Samii VF; Zekas LJ; Scansen BA; Bonagura JD
J Am Vet Med Assoc; 2011 Aug; 239(4):468-79. PubMed ID: 21838584
[TBL] [Abstract][Full Text] [Related]
17. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
[TBL] [Abstract][Full Text] [Related]
18. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
[TBL] [Abstract][Full Text] [Related]
19. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin.
Stanton E; Hansen M; Wijeysundera HC; Kupchak P; Hall C; Rouleau JL;
Eur J Heart Fail; 2005 Jun; 7(4):557-65. PubMed ID: 15921795
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency.
Takemura N; Toda N; Miyagawa Y; Asano K; Tejima K; Kanno N; Arisawa K; Kurita T; Nunokawa K; Hirakawa A; Tanaka S; Hirose H
J Vet Med Sci; 2009 Jul; 71(7):925-9. PubMed ID: 19652480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
